- Shield Therapeutics
- 23 October 2025 11:56:32
Source: Sharecast
The AIM-traded pharmaceutical group, which specialises in iron deficiency treatments, said unaudited net revenues for the three months ended 30 September rose to $13.1m from $12.8m in the second quarter and $7.2m a year earlier.
Prescription volumes increased to around 54,000 from 44,000 in the same period last year, while the average net selling price improved to $237 from $167 in the third quarter of 2024.
“I am very pleased to see Accrufer's strong performance continue into the third quarter of 2025,” said chief executive Anders Lundstrom.
“The combined efforts of the Shield and Viatris Sales team along with our strategic marketing initiatives have driven continued strong performance in the third quarter, marking our strongest quarter on record with a new high in prescription volumes, net selling price, and revenues.”
He added that September alone accounted for more than 40% of quarterly revenue, representing the company’s highest monthly sales to date.
“This performance has reinforced our alignment with full-year performance targets enabling us to stay on track to turning cash flow positive by the end of 2025,” Lundstrom said.
Shield reported cash and cash equivalents of $8.6m at the end of September, down from $10.8m three months earlier, including proceeds from a placing completed during the period.
The company said it remained confident in its financial trajectory as Accrufer continued to expand its market presence in the US.
At 1124 BST, Shield Therapeutics shares were down 0.47% at 7.36p.
Reporting by Josh White for Sharecast.com.
